diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM2015170-77diaendo-6755Research ArticleДиагностика, контроль, лечениеDiagnosis, control, treatmentСоотношение дозы инсулина и массы тела как предиктор эффективности помповой инсулинотерапии у пациентов с сахарным диабетом 2 типа: пилотное исследованиеInsulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept studyhttps://orcid.org/0000-0003-0406-8021ЛевитШмуэльLevitShmuel

MD, PhD,

MD, PhD

shlevit@gmail.comФилипповЮрий ИвановичFilippovYury Ivanovich

научный сотрудник отделения програмного обучения и лечения Института диабета ФГБУ ЭНЦ

MD, Assistance Researcher in Program Education and Therapy Department of the Diabetes Institute

yuriyivanovich@gmail.comhttps://orcid.org/0000-0003-4337-1795CohenOhadCohenOhad

профессор

ohad.cohen@sheba.health.gov.ilWeichmanМарияWeichmanMaria

сотрудник Института диабета

mariahdiet@gmail.comAzuriJosephAzuriJoseph

MD

MD

azuri_yo@mac.org.ilManisteskiYossiManisteskiYossi

MD

MD

manister_y@mac.org.ilЛевитВячеслав МоисеевичLevitVyacheslav Moiseevich

Заведующий отделением профилактики

Head of the Disease prophylaxis department

slava_levit@mail.ruИнститут диабета, Больничная касса Маккаби, Петах-Тиква; Институт эндокринологии, диабета и метаболизма Медицинского Центра Ассута, Тель АвивИзраильInstitute of Endocrinology and Metabolism, Sheba medical center, Tel-AvivIsraelФГБУ "Эндокринологический научный центр" Минздрава России, МоскваРоссияEndocrinology Research Centre, MoscowRussian FederationИнститут эндокринологии и метаболизма, Медицинский центр Шеба, Тель-АвивИзраильInstitute of Endocrinology, Diabetes & Metabolism, Chaim Sheba Medical Center, Tel HashomerIsraelБольничная касса Маккаби, Петах-ТикваИзраильInstitute of Diabetes, Maccabi health Fund, Petah TiqwaIsraelОтдел научных исследований, Больничная касса Маккаби, Тель-АвивИзраильMaccabi Health Fund, department of research, Tel AvivIsraelИнститут диабета, Больничная касса Маккаби, Петах-ТикваИзраильInstitute of Diabetes, Maccabi health Fund, Petah TiqwaIsraelМБУЗ Городская Клиническая больница №8, ЧелябинскРоссияCity Clinical Hospital №8, ChelyabinskRussian Federation2015180320151817077Copyright © Левит Ш., Филиппов Ю.И., Cohen O., Weichman М., Azuri J., Manisteski Y., Левит В.М., 20152015Левит Ш., Филиппов Ю.И., Cohen O., Weichman М., Azuri J., Manisteski Y., Левит В.М.Levit S., Filippov Y.I., Cohen O., Weichman M., Azuri J., Manisteski Y., Levit V.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6755инсулинмасса телаожирениеинсулиновая помпасахарный диабет 2 типапилотное исследованиеinsulinweightobesepumpType 2 diabetesconceptReferencesCurrie CJ, Poole CD, Evans M, et al. Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2013;98(2):668–677. doi: 10.1210/jc.2012-3042.Currie CJ, Poole CD, Evans M, et al. Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2013;98(2):668–677. doi: 10.1210/jc.2012-3042.Левит Ш., Филиппов Ю.И., Горелышев А.С. Сахарный диабет 2 типа: время изменить концепцию. // Сахарный диабет. – 2013. – №1 – С. 91–102. [Levit S, Phillipov YI, Gorelyshev AS. Type 2 Diabetes Mellitus: Time to change the concept. Diabetes Mellitus. 2013;16(1):91–102.] doi: 10.14341/2072-0351-3603Левит Ш., Филиппов Ю.И., Горелышев А.С. Сахарный диабет 2 типа: время изменить концепцию. // Сахарный диабет. – 2013. – №1 – С. 91–102. [Levit S, Phillipov YI, Gorelyshev AS. Type 2 Diabetes Mellitus: Time to change the concept. Diabetes Mellitus. 2013;16(1):91–102.] doi: 10.14341/2072-0351-3603Labrousse-Lhermine F, Cazals L, Ruidavets JB, Hanaire H. Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes. Diabetes Metab. 2007;33(4):253–260. doi: 10.1016/j.diabet.2007.01.007.Labrousse-Lhermine F, Cazals L, Ruidavets JB, Hanaire H. Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes. Diabetes Metab. 2007;33(4):253–260. doi: 10.1016/j.diabet.2007.01.007.Herman WH, Ilag LL, Johnson SL, et al. A Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes. Diabetes Care. 2005;28(7):1568–1573. doi: 10.2337/diacare.28.7.1568.Herman WH, Ilag LL, Johnson SL, et al. A Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes. Diabetes Care. 2005;28(7):1568–1573. doi: 10.2337/diacare.28.7.1568.Raskin P, Bode BW, Marks JB, et al. Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes: A randomized, parallel-group, 24-week study. Diabetes Care. 2003;26(9):2598–2603. doi: 10.2337/diacare.26.9.2598.Raskin P, Bode BW, Marks JB, et al. Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes: A randomized, parallel-group, 24-week study. Diabetes Care. 2003;26(9):2598–2603. doi: 10.2337/diacare.26.9.2598.Bode BW. Insulin Pump Use in Type 2 Diabetes. Diabetes Technol. Ther. 2010;12(S1):S-17-S-21. doi: 10.1089/dia.2009.0192.Bode BW. Insulin Pump Use in Type 2 Diabetes. Diabetes Technol. Ther. 2010;12(S1):S-17-S-21. doi: 10.1089/dia.2009.0192.Testa MA, Turner RR, Hayes JF, Simonson DC. Patient acceptance and satisfaction with intensive insulin therapy in type 2 diabetes: A randomized trial of the insulin pen vs. pump. Diabetes 2001; 50(Suppl 2):A428.Testa MA, Turner RR, Hayes JF, Simonson DC. Patient acceptance and satisfaction with intensive insulin therapy in type 2 diabetes: A randomized trial of the insulin pen vs. pump. Diabetes 2001; 50(Suppl 2):A428.Peyrot M, Rubin RR, Chen X, Frias JP. Associations Between Improved Glucose Control and Patient-Reported Outcomes After Initiation of Insulin Pump Therapy in Patients with Type 2 Diabetes Mellitus. Diabetes Technol. Ther. 2011;13(4):471–476. doi: 10.1089/dia.2010.0167.Peyrot M, Rubin RR, Chen X, Frias JP. Associations Between Improved Glucose Control and Patient-Reported Outcomes After Initiation of Insulin Pump Therapy in Patients with Type 2 Diabetes Mellitus. Diabetes Technol. Ther. 2011;13(4):471–476. doi: 10.1089/dia.2010.0167.Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int. J. Clin. Pract. 2011;65(2):165–171. doi: 10.1111/j.1742-1241.2010.02513.x.Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int. J. Clin. Pract. 2011;65(2):165–171. doi: 10.1111/j.1742-1241.2010.02513.x.Pickup J. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324(7339):705–705. doi: 10.1136/bmj.324.7339.705.Pickup J. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324(7339):705–705. doi: 10.1136/bmj.324.7339.705.Frias JP, Bode BW, Bailey TS, et al. A 16-Week Open-Label, Multicenter Pilot Study Assessing Insulin Pump Therapy in Patients with Type 2 Diabetes Suboptimally Controlled with Multiple Daily Injections. J Diabetes Sci Technol. 2011;5(4):887–893. doi: 10.1177/193229681100500410.Frias JP, Bode BW, Bailey TS, et al. A 16-Week Open-Label, Multicenter Pilot Study Assessing Insulin Pump Therapy in Patients with Type 2 Diabetes Suboptimally Controlled with Multiple Daily Injections. J Diabetes Sci Technol. 2011;5(4):887–893. doi: 10.1177/193229681100500410.Lenhard MJ, Reeves GD. Continuous Subcutaneous Insulin Infusion. Arch. Intern. Med. 2001;161(19):2293. doi: 10.1001/archinte.161.19.2293.Lenhard MJ, Reeves GD. Continuous Subcutaneous Insulin Infusion. Arch. Intern. Med. 2001;161(19):2293. doi: 10.1001/archinte.161.19.2293.Saudek CD, Duckworth WC, Giobbie-Hurder A, et al. Implantable Insulin Pump vs Multiple-Dose Insulin for Non—Insulin-Dependent Diabetes Mellitus. JAMA. 1996;276(16):1322. doi: 10.1001/jama.1996.03540160044031.Saudek CD, Duckworth WC, Giobbie-Hurder A, et al. Implantable Insulin Pump vs Multiple-Dose Insulin for Non—Insulin-Dependent Diabetes Mellitus. JAMA. 1996;276(16):1322. doi: 10.1001/jama.1996.03540160044031.Reznik Y, Morera J, Rod A, et al. Efficacy of Continuous Subcutaneous Insulin Infusion in Type 2 Diabetes Mellitus: A Survey on a Cohort of 102 Patients with Prolonged Follow-Up. Diabetes Technol. Ther. 2010;12(12):931–936. doi: 10.1089/dia.2010.0110.Reznik Y, Morera J, Rod A, et al. Efficacy of Continuous Subcutaneous Insulin Infusion in Type 2 Diabetes Mellitus: A Survey on a Cohort of 102 Patients with Prolonged Follow-Up. Diabetes Technol. Ther. 2010;12(12):931–936. doi: 10.1089/dia.2010.0110.Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-Based, Insulin Dose-Related Hypoglycemia in Hospitalized Patients With Diabetes. Diabetes Care. 2011;34(8):1723–1728. doi: 10.2337/dc10-2434.Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-Based, Insulin Dose-Related Hypoglycemia in Hospitalized Patients With Diabetes. Diabetes Care. 2011;34(8):1723–1728. doi: 10.2337/dc10-2434.Leinung MC, Thompson S, Luo M, et al. Use of Insulin Pump Therapy in Patients with Type 2 Diabetes After Failure of Multiple Daily Injections. Endocr. Pract. 2013;19(1):9–13. doi: 10.4158/ep12104.or.Leinung MC, Thompson S, Luo M, et al. Use of Insulin Pump Therapy in Patients with Type 2 Diabetes After Failure of Multiple Daily Injections. Endocr. Pract. 2013;19(1):9–13. doi: 10.4158/ep12104.or.Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabet. Med. 2005;22(8):1037–1046. doi: 10.1111/j.1464-5491.2005.01597.x.Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabet. Med. 2005;22(8):1037–1046. doi: 10.1111/j.1464-5491.2005.01597.x.Левит Ш., Дзеранова Л.К., Филиппов Ю.И. Алгоритм лечения сахарного диабета 2 типа в свете «гравицентрической концепции». // Ожирение и метаболизм. – 2013. – №3 – С. 50–54. [Levit S, Dzeranova lK, Philippov YI. The gravicentric Concept in type 2 Diabetes: practical implementation. Obesity and metabolism. 2013;(3):50–54.] doi: 10.14341/2071-8713-3865.Левит Ш., Дзеранова Л.К., Филиппов Ю.И. Алгоритм лечения сахарного диабета 2 типа в свете «гравицентрической концепции». // Ожирение и метаболизм. – 2013. – №3 – С. 50–54. [Levit S, Dzeranova lK, Philippov YI. The gravicentric Concept in type 2 Diabetes: practical implementation. Obesity and metabolism. 2013;(3):50–54.] doi: 10.14341/2071-8713-3865.

The authors declare that there are no conflicts of interest present.